Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 1
2016 4
2017 12
2018 26
2019 50
2020 65
2021 133
2022 183
2023 237
2024 276
2025 325
2026 93

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,279 results

Results by year

Filters applied: . Clear all
Page 1
Cefiderocol.
Soriano MC, Montufar J, Blandino-Ortiz A. Soriano MC, et al. Rev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):31-34. doi: 10.37201/req/s01.07.2022. Epub 2022 Apr 22. Rev Esp Quimioter. 2022. PMID: 35488822 Free PMC article. Review.
Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. ...The clinical trial aimed a …
Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales …
New Perspectives on Antimicrobial Agents: Cefiderocol.
McCreary EK, Heil EL, Tamma PD. McCreary EK, et al. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0217120. doi: 10.1128/AAC.02171-20. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34031052 Free PMC article. Review.
No available agent comes close to the broad range of activity afforded by cefiderocol, a novel siderophore-cephalosporin conjugate. The novelty of and need for cefiderocol are clear, but available clinical data are conflicting, leaving infectious diseases specialist …
No available agent comes close to the broad range of activity afforded by cefiderocol, a novel siderophore-cephalosporin conjugate. T …
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
FINDINGS: Between Sept 7, 2016, and April 22, 2019, we randomly assigned 152 patients to treatment, 101 to cefiderocol, 51 to best available therapy. 150 patients received treatment: 101 cefiderocol (85 [85%] received monotherapy) and 49 best available therapy (30 [ …
FINDINGS: Between Sept 7, 2016, and April 22, 2019, we randomly assigned 152 patients to treatment, 101 to cefiderocol, 51 to best av …
Cefiderocol: Clinical application and emergence of resistance.
Wang L, Zhu J, Chen L, Du H. Wang L, et al. Drug Resist Updat. 2024 Jan;72:101034. doi: 10.1016/j.drup.2023.101034. Epub 2023 Dec 18. Drug Resist Updat. 2024. PMID: 38134561 Review.
Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron carrier cephalosporin that achieves drug accumulation through a unique "Trojan horse" strategy into the bacterial periplasm. ...This review …
Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron …
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Sato T, Yamawaki K. Sato T, et al. Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826. Clin Infect Dis. 2019. PMID: 31724047 Free PMC article. Review.
The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to withstand hydrolysis by beta-lactamases. ...This article reviews the discovery and chemistry of cefiderocol, as well as some of the key …
The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to wi …
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Zhanel GG, et al. Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan. ...Cefiderocol is primarily renally excreted unchanged and clearance correlates with creatinine clearance. ...
Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan. ...Cefid …
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Wunderink RG, et al. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058798 Clinical Trial.
We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia. ...Treatment-emergent adverse events were reported in 130 (88%) of 148 participants in the cefiderocol group and 129 (86%) of 150 i …
We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia …
Cefiderocol. Summary and conclusions.
Mensa J, Barberán J. Mensa J, et al. Rev Esp Quimioter. 2022 Sep;35 Suppl 2(Suppl 2):45-47. doi: 10.37201/req/s02.07.2022. Epub 2022 Oct 4. Rev Esp Quimioter. 2022. PMID: 36193985 Free PMC article. Review. No abstract available.
Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM, Rizk JG. El-Lababidi RM, et al. Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10. Ann Pharmacother. 2020. PMID: 32522005 Review.
STUDY SELECTION AND DATA EXTRACTION: All relevant published articles, package inserts, and unpublished meeting abstracts on cefiderocol were reviewed. DATA SYNTHESIS: Cefiderocol is the first siderophore antibiotic to be approved by the FDA. ...Given the higher mort …
STUDY SELECTION AND DATA EXTRACTION: All relevant published articles, package inserts, and unpublished meeting abstracts on cefiderocol …
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.
Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. Ito A, et al. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01454-17. doi: 10.1128/AAC.01454-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29061741 Free PMC article.
A deficiency of the iron transporter PiuA in P. aeruginosa or both CirA and Fiu in Escherichia coli caused 16-fold increases in cefiderocol MICs, suggesting that these iron transporters contribute to the permeation of cefiderocol across the outer membrane. The defic …
A deficiency of the iron transporter PiuA in P. aeruginosa or both CirA and Fiu in Escherichia coli caused 16-fold increases in cefideroc …
1,279 results